Newsroom

news

Voir tout Revue de presse Actualités Publications scientifiques

Scène_Virus-attaque

Past, present and future therapeutic and prophylactic strategies against arenaviruses responsible of human hemorrhagic fever Publications scientifiques

Future Medicine

Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir Publications scientifiques

Fentench_FXDriant_1000-49

L’entreprise biopharmaceutique française Fabentech lance la production de son traitement contre Ebola Actualités

The lancet

Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab’)₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study Publications scientifiques

Future Medicine

Specific polyclonal F(ab’)2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice Publications scientifiques

Prod 1

Fabentech lance un essai clinique de phase I à Singapour pour son produit contre la grippe aviaire H5N1 Actualités

1 2